Our results highlight the potential of cancer immunotherapy with an anti-CD115 mAb, which can inhibit tumor growth by depleting TAMs, synergize with chemotherapy and prevent bone destruction by osteoclasts. This evidence concerns the gene CSF1R and cancer.